The Optimization of an Intravaginal Ring Releasing Progesterone Using a Mathematical Model

[1]  Juergen Siepmann,et al.  Modeling of diffusion controlled drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[2]  D. Mishell,et al.  Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. , 2012, Contraception.

[3]  V. Rocco,et al.  The combined vaginal contraceptive ring, nuvaring, and cerebral venous sinus thrombosis: a case report and review of the literature. , 2012, The Journal of emergency medicine.

[4]  Ignacio M Helbling,et al.  Application of the Refined Integral Method in the mathematical modeling of drug delivery from one-layer torus-shaped devices. , 2012, International journal of pharmaceutics.

[5]  J. Luna,et al.  Mathematical modeling of drug delivery from one-layer and two-layer torus-shaped devices with external mass transfer resistance. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  E. Greenblatt,et al.  A randomized controlled trial of NuvaRing versus combined oral contraceptive pills for pretreatment in in vitro fertilization cycles. , 2011, Fertility and sterility.

[7]  A. Xiang,et al.  Quantifying sustained release kinetics from a polymer matrix including burst effects , 2011 .

[8]  Ignacio M Helbling,et al.  Mathematical modeling of drug delivery from torus-shaped single-layer devices. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[9]  P. Darney,et al.  Vaginal ring contraception. , 2011, Contraception.

[10]  J. Fortenberry,et al.  Acceptability of the vaginal contraceptive ring among adolescent women. , 2010, Journal of pediatric and adolescent gynecology.

[11]  A. Misra,et al.  Other Routes of Protein and Peptide Delivery , 2011 .

[12]  G. Andrews,et al.  Sustained release of proteins from a modified vaginal ring device. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  Thomas J. Smith,et al.  Advances in microbicide vaginal rings. , 2010, Antiviral research.

[14]  Shengrong Guo,et al.  Preparation, characterization and properties of partially hydrolyzed ethylene vinyl acetate copolymer films for controlled drug release. , 2010, International journal of pharmaceutics.

[15]  Ignacio M Helbling,et al.  Modeling of dispersed-drug delivery from planar polymeric systems: optimizing analytical solutions. , 2010, International journal of pharmaceutics.

[16]  A. Faúndes,et al.  Contraceptive vaginal rings: a review. , 2010, Contraception.

[17]  R. Sitruk-Ware,et al.  Progesterone vaginal ring for contraceptive use during lactation. , 2010, Contraception.

[18]  Ignacio M. Helbling,et al.  Modeling of drug delivery from erodible and non-erodible laminated planar devices into a finite external medium , 2010 .

[19]  A. Lamprecht,et al.  Composite microparticles with in vivo reduction of the burst release effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  Moharram A. Khan,et al.  Role of Mathematical Modeling in Controlled Drug Delivery , 2009 .

[21]  J. Siepmann,et al.  Mathematical modeling of drug delivery. , 2008, International journal of pharmaceutics.

[22]  G. Bó,et al.  Room temperature vulcanizing silicone sheaths on a reusable support for progesterone delivery in estrous synchronization treatments in cattle. , 2008, Animal reproduction science.

[23]  Indranil Nandi,et al.  Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone , 2003, AAPS PharmSciTech.

[24]  Mukul Singh,et al.  Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. , 2007, Contraception.

[25]  F. Roumen.  The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. , 2007, Contraception.

[26]  I. Milsom,et al.  Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. , 2006, Contraception.

[27]  J. das Neves,et al.  Gels as vaginal drug delivery systems. , 2006, International journal of pharmaceutics.

[28]  J. Ménard,et al.  Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. , 2006, American journal of obstetrics and gynecology.

[29]  P. Fine,et al.  Patient satisfaction with the use of nuvaring after surgical or medical abortion , 2005 .

[30]  F. Ahsan,et al.  The vagina as a route for systemic drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[31]  N. R. de Melo,et al.  Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. , 2005, Contraception.

[32]  R. Sitruk-Ware,et al.  New delivery systems in contraception: vaginal rings. , 2004, American journal of obstetrics and gynecology.

[33]  D. Craig,et al.  Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[34]  N. Alexander,et al.  Results of a Patient Acceptance Survey Administered to Women in the NuvaRing Premier Program , 2003 .

[35]  C. Loge,et al.  The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. , 2003, Contraception.

[36]  H. Vromans,et al.  In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. , 2002, International journal of pharmaceutics.

[37]  H. Mirzadeh,et al.  Modification of polysiloxane polymers for biomedical applications: a review , 2001 .

[38]  T M Mulders,et al.  Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. , 2001, Fertility and sterility.

[39]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  Mirzadeh Hamid,et al.  A Thermoplastic Rubber Composition for Medical Purposes , 2001 .

[41]  Garg,et al.  The scope and potential of vaginal drug delivery. , 2000, Pharmaceutical science & technology today.

[42]  J. M. Marchetti,et al.  A Rapid Method for Determination of Progesterone By Reversed-Phase Liquid Chromatography from Aqueous Media , 2000 .

[43]  K. Campbell,et al.  High-performance liquid chromatographic determination of 17beta-estradiol and 17beta-estradiol-3-acetate solubilities and diffusion coefficents in silicone elastromeric intravaginal rings. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[44]  I. Fraser,et al.  Estradiol-delivering vaginal rings for hormone replacement therapy. , 1999, American journal of obstetrics and gynecology.

[45]  A. Woolfson,et al.  Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[46]  コズマ，トーマス，ジー．,et al.  Coated with an implantable medical device , 1999 .

[47]  H. Croxatto,et al.  Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. , 1999, Contraception.

[48]  F. Roumen,et al.  Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. , 1999, Contraception.

[49]  V. Pillay,et al.  Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[50]  K. Papadokostaki,et al.  Kinetics of release of a model disperse dye from supersaturated cellulose acetate matrices. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[51]  H. Croxatto,et al.  Fertility regulation in nursing women: IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant® implants, and Copper T 380-A intrauterine devices , 1997 .

[52]  I. Fraser,et al.  Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring. , 1997, Contraception.

[53]  Robert Langer,et al.  Zero-order release of micro- and macromolecules from polymeric devices: the role of the burst effect , 1997 .

[54]  D. Mishell,et al.  Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. , 1997, Contraception.

[55]  V. Brache,et al.  Estradiol delivery by vaginal rings: potential for hormone replacement therapy. , 1997, Maturitas.

[56]  J. W. Moore,et al.  Mathematical comparison of dissolution profiles , 1996 .

[57]  B. Landgren,et al.  Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol. , 1994, Contraception.

[58]  B. Leclerc,et al.  Influence of network characterisitics on diffusion in silicone elastomer , 1993 .

[59]  S. Matlin,et al.  Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from core-loaded rings. , 1992, Contraception.

[60]  L. Illum,et al.  (D) Routes of delivery: Case studies , 1992 .

[61]  M. Elstein,et al.  [Current status of contraceptive vaginal rings]. , 1992, Contraception, fertilite, sexualite.

[62]  R. Bird,et al.  Fenómenos de transporte: Un estudio sistemático de los fundamentos del transporte de materias, energía y cantidad de movimiento , 1982 .

[63]  N. Nielsen,et al.  A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. II-Subjective and objective measures of effects. An international comparative trial. , 1981, Contraception.

[64]  T. Jackanicz.  Levonorgestrel and estradiol release from an improved contraceptive vaginal ring. , 1981, Contraception.

[65]  E. Vartiainen,et al.  The absorption of conjugated oestrogen and sodium oestrone sulphate from the vagina. , 1975, Annales chirurgiae et gynaecologiae Fenniae.

[66]  Y. Chien,et al.  Controlled drug release from polymeric devices. I. Technique for rapid in vitro release studies. , 1974, Journal of pharmaceutical sciences.

[67]  W. L. Robb,et al.  THIN SILICONE MEMBRANES‐THEIR PERMEATION PROPERTIES AND SOME APPLICATIONS , 1968, Annals of the New York Academy of Sciences.

[68]  R. Greenblatt.  The physiologic effectiveness of progesterone vaginal suppositories. , 1954, The Journal of clinical endocrinology and metabolism.